Defense Advanced Research Projects AgencyTagged Content List

Infectious Disease

Relating to ailments caused by pathogens

Showing 17 results for Disease + Med-Devices RSS
Warfighters are travelers, and the bodily inconveniences suffered by travelers, such as jet lag and traveler's diarrhea, can seriously degrade operational readiness and even determine mission success or failure. To maximize warfighter performance, the ADvanced Acclimation and Protection Tool for Environmental Readiness (ADAPTER) program will develop systems that provide warfighters greater control over their own physiology.
The DoD requires timely and comprehensive threat detection to support overall readiness, counter the spread of disease, and promote stabilization missions. State of the art diagnostic and biosurveillance systems are unable to keep pace with disease outbreaks and fail to support decision-making at the time and place of need. The “Detect It with Gene Editing Technologies” (DIGET) program aims to leverage advances in gene editing technologies to develop field-forward diagnostic and biosurveillance technologies that enable detection of any threat, anytime, anywhere.
The Dialysis-Like Therapeutics (DLT) program aims to support force protection and military readiness by improving critical care in low-resource environments and delivering a new tool for rapid response to emerging infectious disease threats. DLT specifically addresses a life-threatening blood infection known as sepsis, but DARPA is working to expand the DLT technology to also mitigate threats from harmful bacteria, viruses, fungi, and toxic agents in the blood.
The Microphysiological Systems (MPS) program supports military readiness by enabling timely evaluation of the safety and efficacy of novel medical countermeasures against a wide range of natural and man-made health threats, including emerging infectious disease and chemical or biological attack. Testing these types of countermeasures is particularly challenging using current methods because it is often both unethical and impractical to evaluate countermeasures using human clinical trials. Instead, the U.S. Food and Drug Administration (FDA) must base its determination of efficacy and toxicity on data from animal studies, despite the fact that animal models have limited relevance to humans and poorly predict effects in humans.
07/10/2015
The White House announced the BRAIN initiative in April 2013. Today, the initiative is supported by several federal agencies as well as dozens of technology firms, academic institutions, scientists and other key contributors to the field of neuroscience. DARPA is supporting the BRAIN initiative through a number of programs, continuing a legacy of DARPA investment in neurotechnology that extends back to the 1970s.